Overview

* Pulmonx Q3 2025 revenue rises 5% yr/yr to $21.5 mln

* International revenue grows 15% yr/yr, U.S. revenue up 1%

* Pulmonx ( LUNG ) reports Q3 net loss of $14 mln, marginally lower than last year

Outlook

* Pulmonx ( LUNG ) expects 2025 revenue between $89 mln and $90 mln

* Company anticipates 2025 gross margin of approximately 73%

* Pulmonx ( LUNG ) forecasts 2025 operating expenses of $125 mln to $126 mln

Result Drivers

* INTERNATIONAL REVENUE GROWTH - Driven by global adoption of Zephyr Valve procedures

* ZEHPYR VALVE ADOPTION - Co attributes revenue growth to continued commercial execution and global adoption of Zephyr Valve procedures

* OPERATING EXPENSES - Increase in operating expenses due to clinical, development, and commercial investments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.34

Q3 Net -$13.96

Income mln

Q3 Gross $16.05

Profit mln

Q3 -$14.39

Income mln

From

Operatio

ns

Q3 -$13.83

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Pulmonx Corp ( LUNG ) is $4.50, about 53.6% above its November 11 closing price of $2.09

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)